Assignee
AMGEN FREMONT INC
US·44 granted patents·9 pending applications·1,727 citations·filing 2000–2019
Top patents by PatentIndex Score
53 records- 0198US7824679B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2007·Granted Nov 2, 2010·87 cites·19 claims
- 0298US7411057B2Nucleic acids encoding human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2005·Granted Aug 12, 2008·87 cites·38 claims
- 0397US8883984B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2013·Granted Nov 11, 2014·38 cites·24 claims
- 0497US7807797B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2007·Granted Oct 5, 2010·76 cites·25 claims
- 0597US7807798B2Human monoclonal antibodies to epidermal growth factor receptorAMGEN FREMONT INC·Filed 2005·Granted Oct 5, 2010·37 cites·11 claims
- 0697US7736644B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2004·Granted Jun 15, 2010·77 cites·115 claims
- 0797US7628986B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2004·Granted Dec 8, 2009·119 cites·83 claims
- 0897US7626012B2Nucleic acid molecules which encode antibodies that bind CD40AMGEN FREMONT INC·Filed 2008·Granted Dec 1, 2009·53 cites·21 claims
- 0997US7618633B2Antibodies that bind CD40 and methods of treating cancer and enhancing immune responsesAMGEN FREMONT INC·Filed 2007·Granted Nov 17, 2009·63 cites·45 claims
- 1097US7435871B2Transgenic animals bearing human Igλ light chain genesAMGEN FREMONT INC·Filed 2002·Granted Oct 14, 2008·173 cites·9 claims
- 1196US7566772B2Antibodies against interleukin-1βAMGEN FREMONT INC·Filed 2006·Granted Jul 28, 2009·72 cites·19 claims
- 1295US7423128B2Anti-properdin antibodies, and methods for making and using sameAMGEN FREMONT INC·Filed 2004·Granted Sep 9, 2008·82 cites·34 claims
- 1395US7285269B2Antibodies directed to tumor necrosis factorAMGEN FREMONT INC·Filed 2003·Granted Oct 23, 2007·101 cites·35 claims
- 1494US7964193B2Antibodies against interleukin-1 βAMGEN FREMONT INC·Filed 2009·Granted Jun 21, 2011·29 cites·12 claims
- 1594US7932372B2Antibodies to MAdCAMAMGEN FREMONT INC·Filed 2006·Granted Apr 26, 2011·30 cites·52 claims
- 1694US7728113B2Methods of treating arthritic conditions with antibodies to M-CSFAMGEN FREMONT INC·Filed 2007·Granted Jun 1, 2010·21 cites·27 claims
- 1793US7815907B2Antibodies to insulin-like growth factor I receptorAMGEN FREMONT INC·Filed 2005·Granted Oct 19, 2010·21 cites·97 claims
- 1893US7547817B2Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regionsAMGEN FREMONT INC·Filed 2005·Granted Jun 16, 2009·25 cites·26 claims
- 1993US7537762B2Human monoclonal antibodies to activin receptor-like kinase-1AMGEN FREMONT INC·Filed 2006·Granted May 26, 2009·34 cites·15 claims
- 2093US7498420B2Antibodies to c-MetAMGEN FREMONT INC·Filed 2004·Granted Mar 3, 2009·60 cites·34 claims
- 2193US7378091B2Antibodies against carbonic anhydrase IX (CA IX) tumor antigenAMGEN FREMONT INC·Filed 2002·Granted May 27, 2008·44 cites·25 claims
- 2293US7135174B2Antibodies directed to PDGFD and uses thereofAMGEN FREMONT INC·Filed 2002·Granted Nov 14, 2006·47 cites·4 claims
- 2392US7807159B2Antibodies to myostatinAMGEN FREMONT INC·Filed 2006·Granted Oct 5, 2010·102 cites·14 claims
- 2491US9963508B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2014·Granted May 8, 2018·6 cites·13 claims
- 2590US8821869B2Treatment methods using c-Met antibodiesAMGEN FREMONT INC·Filed 2013·Granted Sep 2, 2014·13 cites·15 claims
- 2690US7579186B1Human monoclonal antibody against TGF-β type II receptor and medicinal use thereofAMGEN FREMONT INC·Filed 2000·Granted Aug 25, 2009·51 cites·29 claims
- 2790US7318925B2Methods of use for antibodies against parathyroid hormoneAMGEN FREMONT INC·Filed 2004·Granted Jan 15, 2008·30 cites·27 claims
- 2890US7288253B2Antibodies directed to parathyroid hormone (PTH) and uses thereofAMGEN FREMONT INC·Filed 2003·Granted Oct 30, 2007·32 cites·16 claims
- 2989US7982024B2Antibodies to insulin-like growth factor I receptorAMGEN FREMONT INC·Filed 2010·Granted Jul 19, 2011·11 cites·24 claims
- 3088US7867494B2Anti-IgE antibodiesAMGEN FREMONT INC·Filed 2008·Granted Jan 11, 2011·30 cites·14 claims
- 3188US7265212B2Anti-CD45RB antibodiesAMGEN FREMONT INC·Filed 2002·Granted Sep 4, 2007·33 cites·8 claims
- 3285US7572444B2Binding proteins specific for human matriptaseAMGEN FREMONT INC·Filed 2005·Granted Aug 11, 2009·12 cites·17 claims
- 3384US7993643B2Uses of human monoclonal antibodies against oxidized LDL receptorAMGEN FREMONT INC·Filed 2007·Granted Aug 9, 2011·8 cites·28 claims
- 3483US7625549B2Determining the risk of human anti-human antibodies in transgenic miceAMGEN FREMONT INC·Filed 2005·Granted Dec 1, 2009·3 cites·24 claims
- 3582US7429380B2Production of a multimeric protein by cell fusion methodAMGEN FREMONT INC·Filed 2003·Granted Sep 30, 2008·5 cites·13 claims
- 3681US11492411B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2019·Granted Nov 8, 2022·0 cites·20 claims
- 3781US7820877B2Transgenic mammals having human IG loci including plural Vh and Vk regions and antibodies produced therefromAMGEN FREMONT INC·Filed 2005·Granted Oct 26, 2010·3 cites·10 claims
- 3881US7771951B2Antibody categorization based on binding characteristicsAMGEN FREMONT INC·Filed 2002·Granted Aug 10, 2010·5 cites·52 claims
- 3979US10280219B2Antibodies to M-CSFAMGEN FREMONT INC·Filed 2017·Granted May 7, 2019·1 cites·12 claims
- 4078USRE45847EAntibodies to MAdCAMAMGEN FREMONT INC·Filed 2014·Granted Jan 19, 2016·2 cites·52 claims
- 4175US10508153B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2015·Granted Dec 17, 2019·1 cites·61 claims
- 4270US2010098694A1Antibodies to cd40AMGEN FREMONT INC·Filed 2009·Application pending·0 cites
- 4369US2019202905A1Antibodies to m-csfAMGEN FREMONT INC·Filed 2019·Application pending·0 cites
- 4465US9234041B2Antibodies to insulin-like growth factor I receptorAMGEN FREMONT INC·Filed 2013·Granted Jan 12, 2016·0 cites·20 claims
- 4562US9718883B2Antibodies to M-CSFAMGEN FREMONT INC·Filed 2015·Granted Aug 1, 2017·0 cites·39 claims
- 4662US2013344514A1Reducing the risk of human anti-human antibodies through v gene manipulationAMGEN FREMONT INC·Filed 2013·Application pending·0 cites
- 4761US7754433B2Identification of high affinity molecules by limited dilution screeningAMGEN FREMONT INC·Filed 2002·Granted Jul 13, 2010·3 cites·20 claims
- 4861US2015250152A1Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefromAMGEN FREMONT INC·Filed 2014·Application pending·0 cites
- 4959US2016152713A1Antibodies to cd40AMGEN FREMONT INC·Filed 2015·Application pending·0 cites
- 5052US2014105905A1High Affinity Fully Human Monoclonal Antibodies To Interleukin-8 And Epitopes For Such AntibodiesAMGEN FREMONT INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →